Benjamin Hohl Sells 4,250 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 4,250 shares of the business’s stock in a transaction that occurred on Friday, September 27th. The stock was sold at an average price of $24.27, for a total transaction of $103,147.50. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Benjamin Hohl also recently made the following trade(s):

• On Monday, September 30th, Benjamin Hohl sold 2,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.33, for a total transaction of $50,660.00.
• On Tuesday, August 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.54, for a total value of $95,795.00.
• On Wednesday, July 31st, Benjamin Hohl sold 991 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.53, for a total value of $27,282.23.
• On Monday, July 29th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $26.68, for a total transaction of $140,070.00.
• On Friday, July 12th, Benjamin Hohl sold 3,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.07, for a total transaction of $75,210.00.

Enliven Therapeutics Stock Up 1.8 %

Shares of Enliven Therapeutics stock traded up $0.46 on Tuesday, hitting $26.00. 849,423 shares of the company traded hands, compared to its average volume of 257,450. The company has a market cap of $1.22 billion, a PE ratio of -14.14 and a beta of 1.09. Enliven Therapeutics, Inc. has a 12-month low of $9.80 and a 12-month high of $27.67. The company has a 50-day moving average price of $23.14 and a 200 day moving average price of $21.71.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.17. Equities research analysts anticipate that Enliven Therapeutics, Inc. will post -1.98 EPS for the current year.

Hedge Funds Weigh In On Enliven Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Janus Henderson Group PLC grew its position in Enliven Therapeutics by 74.8% during the 1st quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock worth $12,604,000 after acquiring an additional 305,397 shares during the last quarter. First Turn Management LLC acquired a new stake in shares of Enliven Therapeutics in the 2nd quarter valued at approximately $9,657,000. Marshall Wace LLP bought a new position in Enliven Therapeutics during the second quarter worth $4,489,000. Baker BROS. Advisors LP acquired a new stake in Enliven Therapeutics during the 1st quarter worth approximately $2,020,000. Finally, Bank of New York Mellon Corp grew its position in shares of Enliven Therapeutics by 49.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company’s stock worth $2,667,000 after purchasing an additional 37,632 shares in the last quarter. Institutional investors own 95.08% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on ELVN shares. Baird R W raised Enliven Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th. HC Wainwright restated a “buy” rating and issued a $37.00 target price on shares of Enliven Therapeutics in a research report on Tuesday. Finally, Robert W. Baird initiated coverage on shares of Enliven Therapeutics in a research note on Tuesday, June 11th. They set an “outperform” rating and a $32.00 price objective on the stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.